---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-019592"
form_type: "8-K"
ticker: "LONA"
cik: "0001620463"
company_name: "LeonaBio, Inc."
filed_at: "2022-10-17T23:59:59+00:00"
generated_at: "2026-06-23T03:20:26.368301+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Athira gets positive interim analysis for Alzheimer's drug fosgonimeton, study continues

## Summary
- Independent data monitoring committee recommended continuation of LIFT-AD after unblinded interim analysis.
- Adding fewer than 150 patients (total <300 with no background therapy) will power study for primary endpoint.
- Interim analysis in ~100 patients not on background therapy corroborated prior ACT-AD Phase 2 findings.
- Company targets enrollment completion mid-2023 and topline data in early 2024.
- CEO cites strong balance sheet to execute through key data readouts.

## SEC filing metadata
- accession: 0000950170-22-019592
- form_type: 8-K
- ticker: LONA
- cik: 0001620463
- company_name: LeonaBio, Inc.
- filed_at: 2022-10-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1620463/000095017022019592/0000950170-22-019592-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1620463/000095017022019592/atha-20221017.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-019592
- JSON: https://secwatch.observer/filing/0000950170-22-019592.json
- Plain text: https://secwatch.observer/filing/0000950170-22-019592.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.